Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mihaela M Druta, MD
H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center
Principal Investigator - Patrick A. Thompson, MD
University of North Carolina, Chapel Hill
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama at Birmingham
Birmingham, Alabama, United States
- Children'S Hospital of Los Angeles, Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Children'S Hospital of Colorado
Aurora, Colorado, United States
- Connecticut Children'S Medical Center
Hartford, Connecticut, United States
- Alfred I Dupont Hospital for Children
Wilmington, Delaware, United States
- Shand'S Hospital for Children at the University of Florida
Gainesville, Florida, United States
- Nemours Children'S Hospital
Jacksonville, Florida, United States
- University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- Nemours Children'S Clinic
Orlando, Florida, United States
- Johns Hopkins All Children'S Hospital
St. Petersburg, Florida, United States
- H. Lee Moffitt Cancer Center and Research Institute, Coordinating Center
Tampa, Florida, United States
- University of Kentucky, Markey Cancer Center
Lexington, Kentucky, United States
- Johns Hopkins University, Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
- University of North Carolina at Chapel Hill, Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Carolina Medical Center, Levine Cancer Institute
Charlotte, North Carolina, United States
- Duke Health
Durham, North Carolina, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Nationwide Children'S Hospital
Columbus, Ohio, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center
Dallas, Texas, United States
- University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Oct 2019
- Primary completion
- 29 Dec 2024
- Completion
- 30 Apr 2026
- Last update posted
- 5 Feb 2026
- Registered enrollment
- 21
- Registry id
- NCT03628209
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.